US Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
This is the first drug approved by the FDA for PPMS, says a USFDA statement.
Ocrevus is an intravenous infusion given by a healthcare professional.
MS therapy not only provides another treatment option for those with relapsing MS, but also provides an approved therapy for those with primary progressive MS.
MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.
US FDA: Know More - Founded: 30 June 1906
- Headquarters: Silver Spring, Maryland, United States
- Number of employees: 14,824 (2010)
- Annual budget: 4.36 billion USD (2012)
- Subsidiaries: Center for Drug Evaluation and Research, more
- Founders: Theodore Roosevelt, Harvey Washington Wiley
- Parent organization: United States Department of Health & Human Services
